Strategic Cooperation | H∏↓σπaibu Pharmaceutical and Kelin •®Likang have reached a strategic"<$ cooperation.

On November 12, 2021, the signi¶‌ng ceremony of the str✔≥↑✔ategic cooperation agreement between ‍ ∏Beijing Haibu Pharmac÷§¥£eutical Technology Co., Ltd∞‍™. and Beijing Kelin Likang Medical Reσ♣σ¶search Co., Ltd. was held at Haibu α∞±Pharmaceutical. Mr. Xu Yu, ©↑÷∞founder and CEO of Kelin✘εεγ Likang, Mr. Zhou Jianguo, S ∏enior Vice President of Public Affair φ←s, and representativφ☆es from the Business Development D>βαepartment attended the signing cere<↓←mony with the Haibu Pharmaceutical α★representative team.

Photo: Group photo of r₩¥© epresentatives from both pa→∑☆✔rties at the strategic cooperaσ€↑ tion signing ceremony.

Ms. Liu Changru, Chairman and Gener ♦•&al Manager of Haibu Pharε≈₽≤maceutical, and Mr. Xu₩↕δ→ Yu, founder and CEO of Kelin Likβ€π±ang, delivered speeches✘<$φ at the signing ceremony,π♦ elaborating on their ♣✔ €respective companies' business charac→£ teristics and advant™®>'ages, and expressing expectations ≤♦±'for future cooperation between both₹® ₩ parties. Based on Haibu Pharmaceutica​βl's technical strength ÷β✘and advantages in chemical ✔ βdrug research and developmen©&t, Kelin Likang has rich research r‍ε∞ esources and experience iβφ >n clinical trials.Customer demand-oriented™↔™, based on mutual trust"With this concept in mind≤↑$, we will work together←↑ sincerely to provide more professio↑≥γ£nal and comprehensive serv™•ices for upstream and downstream ₽¶enterprises, institutions, and partne≤Ω∞rs in the industry, pr'>omote faster market accessε₩ for new drugs and good d♣∏rugs, benefit patients, ↔ ♦and create value.

Mr. Zhou Jianguo, Vice President ≠✔of Public Affairs at Kelin ≈×Likang participated in the signing ce÷↑&πremony and delivered a spe≠₩β↔ech introducing Kelin Lika♥♥ng's rapid developmen¶←±≈t process in recent years as well ✘₽Ω∞as its full-process s✔'ervice capabilities for clinica×φ☆→l trials.

In the future, both par÷®ties will carry out multi€✘×-faceted close cooperationπ£φ in areas such as innovative drug pha¥•rmaceutical research, bioequiv∏♣λαalence testing for gener↓®×ic drugs, confirmatory clinical tri>×als, marketing authorization holde¥♥r (MAH), pharmacovigilance,≠∞≥ custom development of place∑×bo or control drugs to achieve↓Ω collaborative innovat₽✔αion and support industryε✘δ development.

About Beijing Kelin Lika↕ ×ng Medical Research Co., Lσ∞>td.

Beijing Kelin Likang Medical Resea >rch Co., Ltd. is a comprehensiv™ε<e medical technology service∏↔÷ provider dedicated to clinical &π✔operations, drug regulatβ↔¥ory registration, med&®®φical writing, biostatistics σ™and data management, pharmacovigilance,↕↓↓ call center services, quality assura®β₩nce training and consulting service&δσεs.

Kelin Likang is headφ÷♦¥quartered in Beijing with physical oσ∑&↔ffices in Shanghai, Gua¥δngzhou,Tianjin ,Chengdu ,Xi'an ✘¥ ,Shenyang ,Suzhou ,Nan∑₩♦‍jing ,and Taipei among other loα​cations; it also has resi•₩±dent monitors in over 20 cities. It has♣>φα overseas offices in places like the→× United States ,the United Kin₩®≠gdom ,Canada ,and Singap✔$Ωore . Currently it has an interna"♦tional professional tγ™eam of nearly 800 people.

Since its establishment in 2009,Ke&←lin Likang has actively participated iΩ∞•"n clinical research and academic↓♠♣ promotion in domestic and in ® <ternational medical fields providΩ∞γing specialized clinical services ♥♥∏to pharmaceutical companies authoritati<✘™≥ve academic institutions clinical t€→↕rial research institutions e↔≤>€xperts doctors etc hel¶"↑ping patients achieve better health w>Ωhile rapidly growing i•'nto one of China's major ÷↕ contract research organizations>σ☆ for clinical trials wλ←€‍ith high-quality service reasonab>αle prices a highly qualifie×σ≤d team a complete quality βΩ‍₩management system high-quality eff ₹icient service rich ex¥♥perience in clinical research resulti‍‌→ng in a repurchase rφ‌♥ate as high as 85%.

About Beijing Haibu Pha&≠αδrmaceutical Technology♣£φ Co., Ltd.

Beijing Haibu Pharmaceu≥₽₽tical Technology Co., Ltd. has " rich successful experienc•‍e in the R&D of sσλmall molecule chemical ≈δ©drugs. In recent yearασ∞s，Haibu Pharmaceutical has activφ₩→<ely explored compound design sγ©tructural modification synthesis‌'εβ process optimization formulation tecφ ←∞hnology improvement crystaλ✘€l form challenges etc ≠©related to small molecule chemical♦←  innovative drugs achiev∏§ε&ing some results.The Haibu te• •±am is well-versed with laws regulations•↔Ω technical guidelines related to'↕ → small molecule chemical drug R&am₹♥​♦p;D possessing full-process efficient$÷∞ project management capabilit•↕±←ies from project eval₽∑αuation patent strategy design precliniγ‌cal research clinical trial ♣>≤≤management drug registration to obtainiΩ÷ng market access qualificat γions.